Only in Titles

Search results for: 250mg

paperclip

Error loading info... Pleas try again later.
paperclip

#34508391   // To Up

A case of lupus nephritis flare-up in severe COVID-19 infection.

The novel Coronavirus disease 2019 (COVID-19) had rapidly spread and became a worldwide pandemic since its detection in Wuhan, China. The disease has caused significant morbidity and mortality, particularly among patients with comorbidities. The current treatment involves supportive management alongside antiviral therapy and immunosuppressant therapy in severely affected patients. We describe a case of a patient with underlying lupus nephritis (LN) who presented with severe COVID-19 infection and concomitant LN flare with acute kidney injury (AKI). The patient was treated with antiviral therapy, Favipiravir, considering his risk of developing severe COVID-19 infection. As the patients would usually have AKI alongside LN flare, we administered initial steroid therapy at a lower dose (Methylprednisolone 50mg daily) and oral hydroxychloroquine despite the initial concerns on immunosuppressant usage in COVID-19 infections. Although our patient recovered relatively well from COVID- 19 infection, he continued to have positive reverse transcriptase-polymerase chain reaction (RT-PCR) nasopharyngeal swab for COVID-19 up to 29 days of illness. His kidney function stabilised despite having persistent nephrotic range proteinuria. Hence, the attending team decided to pulse the patient with a high dose steroid (IV Methylprednisolone 250mg OD for three days) after two weeks of illness despite the persistent positive swab. The patient's condition continued to improve, and this case illustrates an approach in treating COVID-19 with concomitant active immune-mediated glomerulonephritis. We find that it is safe to institute high dose immunosuppressant in recovered COVID-19 patients two weeks after the illness.
A S Yusuf, X K Cheong, M Rozita, P Periyasamy, M Ruslinda

2981 related Products with: A case of lupus nephritis flare-up in severe COVID-19 infection.



Related Pathways

paperclip

#34466600   2020/08/16 To Up

Evaluation of Impacts of Cellular Metabolism on the Migration of Ovarian Cancer Cells by Two in Vitro Assays: A Method Comparison Study.

Alteration of metabolic pathways in cancer cells can intensely modulate their migration as an important step in invasion and metastasis. Ketogenic diet showed some contradictory results in cancer patients. In this study the impact of metabolic reprogramming of A2780CP as a model of ovarian cancer stem-like cells on cell migration by two in vitro methods: wound healing and soft agar colony-forming assays.
Hossein Ghahremani, Majid Sirati-Sabet, Siamak Salami

1956 related Products with: Evaluation of Impacts of Cellular Metabolism on the Migration of Ovarian Cancer Cells by Two in Vitro Assays: A Method Comparison Study.

96 assays96 assays

Related Pathways

paperclip

#34434051   2021/08/18 To Up

Efficacy and Safety of Apatinib for Elderly Patients with Advanced or Metastatic Gastric Cancer After Failure of at Least First-Line Chemotherapy: A Multi-Center, Single-Arm, Phase II Study.

Apatinib improves progression-free survival and overall survival with an acceptable safety profile in Chinese patients with chemotherapy-refractory advanced or metastatic gastric cancer. However, the efficacy and safety of apatinib are unclear for elderly patients. This study was undertaken to prospectively investigate the efficacy and safety of apatinib for elderly patients with unresectable advanced or metastatic gastric cancer, who experienced progression to at least one lines of chemotherapy.
Dengfeng Ren, Guoxiu Wang, Yu Zhang, Jie Kan, Qiuxia Dong, Junhui Zhao, Faxiang Ji, Hao Li, Yushuang Luo, Mingzhe Lin, Guoyuan Li, Zhibo Liu, Xinfu Ma, Qijing Guo, Fuxing Zhao, Guoshuang Shen, Jiuda Zhao

1342 related Products with: Efficacy and Safety of Apatinib for Elderly Patients with Advanced or Metastatic Gastric Cancer After Failure of at Least First-Line Chemotherapy: A Multi-Center, Single-Arm, Phase II Study.



Related Pathways

paperclip

#34432988   2021/08/25 To Up

Genistein and Momordica charantia L. prevents oxidative stress and upregulate proglucagon and insulin receptor mRNA in diabetic rats.

Type 2 diabetes (T2D) occur as a result of insulin resistance and malfunction in insulin signaling. Controlling hyperglycemia and activation of insulin signaling are important in the management of T2D. The study aimed to evaluate the effect of Genistein and Momordica charantia L. fruit on oxidative stress, markers of inflammation, and their role on proglucagon and insulin receptor mRNA expression by RT-PCR in diabetic rats. Thirty-five albino rats were divided into seven groups (n=5). Group I (non-diabetic) and group II (diabetic control) were treated with distilled water, groups III and IV received 250mg/kg and 500mg/kg lyophilized MCF respectively. Groups V and VI received 10mg/kg and 20mg/kg Genistein respectively while group VII received 500mg/kg Metformin. The administration lasted for 28 days. MCF and Genistein significantly reduced IL-1β and TNFα levels that was elevated in serum of diabetic rats. Treatment with MCF and Genistein significant increased the expression of proglucagon mRNA in the small intestine and insulin receptor mRNA in the liver of diabetic rats. In conclusion, MCF and Genistein ameliorate type 2 diabetes complications by preventing the loss of insulin-positive cells, inhibiting IL-1β and TNFα and up-regulating proglucagon and insulin receptor mRNA expression. Novelty: • MCF and Genistein has an inhibitory effect on diabetic induced IL-1β and TNFα production. • MCF and Genistein up-regulates proglucagon and insulin receptor mRNA expression.
Wusa Makena, Abdullahi Ibrahim Iliya, Joseph Olajide Hambolu, James Abrak Timbuak, Uduak Emmanuel Umana, Nathan Isaac Dibal

1597 related Products with: Genistein and Momordica charantia L. prevents oxidative stress and upregulate proglucagon and insulin receptor mRNA in diabetic rats.

0.1 mg100ug100ug50 ug 100ug1 ml100ug50 ug 100ul100ug

Related Pathways

paperclip

#34427709   2021/08/24 To Up

[Renaissance of mouse favus : Retrospective analysis of Trichophyton quinckeanum infections at Jena University Hospital in the period 2015-2020].

The number of Trichophyton quinckeanum infections has increased significantly in recent years. In 2020 in particular, the number of cases increased fivefold compared to 2015. Infections multiplied, especially in the second half of the year, which correlated with the upsurge in field mouse populations. Typical vectors are mice and rats as well as dogs and cats, which hunt the rodents. The animals are usually asymptomatic. In humans, on the other hand, the course is usually more inflammatory corresponding to other zoophilic mycoses. Typical clinical manifestations of the infections are tinea corporis and tinea capitis. Treatment of T. quinckeanum infections is similar to other dermatophyte infections, depending on the severity, location and age of the patient as well as the immune status, previous illnesses and medication. The duration of local therapy should be at least 4 weeks and continued for up to 14 days after the normalization of the skin presentation. Systemic treatment should take place with terbinafine 250 mg once a day orally (in adults). Alternatives are itraconazole, fluconazole and griseofulvin. Only the preparation griseofulvin, which is no longer available in Germany, is approved for children. Alternatively, terbinafine, itraconazole or fluconazole can also be used in children as an "off-label" treatment in an individual healing attempt.
D M Gregersen, A Burmester, L Ludriksone, S Darr-Foit, C Hipler, C Wiegand

2281 related Products with: [Renaissance of mouse favus : Retrospective analysis of Trichophyton quinckeanum infections at Jena University Hospital in the period 2015-2020].

100 μg4 Membranes/Box2 1 mg100 μg8 Sample Kit1 kit(96 Wells)100 μg100ug Lyophilized25 1-8 Sample Kit100.00 ug

Related Pathways

paperclip

#34394322   // To Up

Anti-inflammatory potential of dichloromethane leaf extracts of (Labill) and (Fresenius) in mice.

Inflammation is an immune response characterized by swelling, redness, pain and heat. Inflammation is mainly managed using conventional medicines that are associated with many side effects. Plant-based remedies are considerably better alternative therapies for they have fewer side effects.
Joseph Kiambi Mworia, Cromwell Mwiti Kibiti, Joseph Jn Ngeranwa, Mathew Piero Ngugi

2641 related Products with: Anti-inflammatory potential of dichloromethane leaf extracts of (Labill) and (Fresenius) in mice.

100 μg100ug0.1 mg100 μg100ug Lyophilized100 μg100 μg100ug Lyophilized100ug

Related Pathways

paperclip

#34331221   2021/07/30 To Up

Mechanism of Cr(VI) reduction by Lysinibacillus sp. HST-98, a newly isolated Cr (VI)-reducing strain.

Facing the increasingly severe Cr(VI) pollution, bioreduction has proved to be an eco-friendly remediation method. An isolated strain identified as Lysinibacillus can relatively reduce Cr(VI) well. Even if the concentration of Cr(VI) increased to 250mg/L, the strain HST-98 could also grow and remove Cr(VI) well. After optimization of reaction conditions, the optimal pH, temperature, and electron donor are 8~9, 36°C, and sodium lactate, respectively. Coexisting metal ions such as Cu, Co, and Mn are beneficial to reduce Cr(VI), while Zn, Ni, and Cd are just the opposite. What is more, the mechanism of the reduction by the strain HST-98 is chiefly mediated by intracellular enzymes. After gene sequence homology blast and analysis, the genes and enzymes related to chromium metabolism in strain HST-98 have been annotated, which helps us to further understand the reduction mechanism of the strain HST-98. In general, Lysinibacillus sp. HST-98 is a potential candidate to repair the Cr(VI)-contaminated sites.
Jia Chen, Xiaoguang Li, Longzhan Gan, Guangyang Jiang, Ruoshi Zhang, Zhe Xu, Yongqiang Tian

2619 related Products with: Mechanism of Cr(VI) reduction by Lysinibacillus sp. HST-98, a newly isolated Cr (VI)-reducing strain.

200 ug5 mg100ug Lyophilized1 mg100ug100ug Lyophilized0.2 mg100ug100ug Lyophilized500100 μg500

Related Pathways

paperclip

#34329691   2021/07/27 To Up

Amelioration of user experiences and glycaemic outcomes with an Advanced Hybrid Closed Loop System in a real-world clinical setting.

Automation in diabetes technology is rapidly evolving. The aim was to evaluate the real-world glycemic outcomes and user acceptance after 3 months of using the Medtronic 780G Advanced Hybrid Closed-Loop (AHCL) system.
Pilar Isabel Beato-Víbora, Fabiola Gallego-Gamero, Ana Ambrojo-López, Estela Gil-Poch, Irene Martín-Romo, Francisco Javier Arroyo-Díez

2099 related Products with: Amelioration of user experiences and glycaemic outcomes with an Advanced Hybrid Closed Loop System in a real-world clinical setting.



Related Pathways

paperclip

#34275813   // To Up

Modification and validation of liquid chromatographic method for the quantification of ciprofloxacin in human plasma and its application to a bioavailability study.

A new simple, accurate, precise and sensitive liquid chromatographic method for the analysis of Ciprofloxacin in human plasma, suitable for quantification of drug was developed and validated using HPLC-UV method. The analyte was chromatographically separated from endogenous plasma components on a C-18 reversed phase column (5µm, 25cm × 0.46cm) and detected at 278nm. The sample pretreatment was carried out with acetonitrile on 200µl of plasma. The Lower limit of quantification (LLOQ) was 0.04 µg/ml with linearity in the range 0.04-4 µg/ml and coefficient of correlation value (R)>0.995. The method was successfully validated as per current FDA guidance for necessary parameters and applied to a pilot bioavailability study conducted on six healthy volunteers with marketed Ciprofloxacin 250mg immediate release tablets. The plasma concentrations were subjected to non-compartmental analysis for calculation of pharmacokinetic parameters like C, T, AUC, AUC and t etc. The mean values of C and T were found to be 1.35±0.09µg/ml and 1.25±0.27h respectively while for other pharmacokinetic parameters including AUC, AUC were found to be 5.98±0.96 μg/ml×h and 6.34±1.07μg/ml×h. The drug exhibited half-life (t) of 3.94±0.33h. The obtained results proved the suitability of the method for routine pharmacokinetic studies of Ciprofloxacin.
Muhammad Talha Usmani, Muhammad Harris Shoaib, Fahad Siddiqui, Farrukh Rafiq Ahmed, Sabahat Jabeen, Rehana Saeed, Kamran Ahmed, Sadaf Farooqi, Tazeen Hussain, Syed Muhammad Imran

2296 related Products with: Modification and validation of liquid chromatographic method for the quantification of ciprofloxacin in human plasma and its application to a bioavailability study.

100ul25 0.1 mg 100ul 100ul 100ul100 96T

Related Pathways